Lessons from the past: Opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies

Pediatric Blood and Cancer

Volumn 58, Issue 3, 2012, Pages 334-343

  Hudson, Melissa M ^a,b   Neglia, Joseph P ^c   Woods, William G ^d,e   Sandlund, John T ^a,b   Pui, Ching Hon ^a,b   Kun, Larry E ^a,b   Robison, Leslie L ^a,b   Green, Daniel M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

Childhood cancer therapy; Late effects; Long term follow up

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC ANTIMETABOLITE; ASPARAGINASE; BLEOMYCIN; CHLORMETHINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IMATINIB; MERCAPTOPURINE; METHOTREXATE; NELARABINE; PREDNISONE; PROCARBAZINE; TIOGUANINE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; BRAIN RADIATION; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVOR; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; LAPAROTOMY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC PROTOCOLS; CHILD; COMBINED MODALITY THERAPY; HEMATOLOGIC NEOPLASMS; HODGKIN DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVORS; TREATMENT OUTCOME;

EID: 84855801388     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23385     Document Type: Review

References (100)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948; 238: 787-793.
3. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood 1997; 90: 4243-4251.
4. Pinkel D. Five-year follow-up of "total therapy" of childhood lymphocytic leukemia. JAMA 1971; 216: 648-652.
5. Aur RJ, Simone JV, Hustu HO, et al. A comparative study of central nervous system irradiation and intensive chemotherapy early in remission of childhood acute lymphocytic leukemia. Cancer 1972; 29: 381-391.
6. Nesbit ME Jr, Sather HN, Robison LL, et al. Presymptomatic central nervous system therapy in previously untreated childhood acute lymphoblastic leukaemia: Comparison of 1800rad and 2400rad. A report for Children's Cancer Study Group. Lancet 1981; 1: 461-466.
7. Sallan SE, Hitchcock-Bryan S, Gelber R, et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983; 43: 5601-5607.
8. Ritter J, Creutzig U, Reiter A, et al. Childhood leukemia: Cooperative Berlin-Frankfurt-Munster trials in the Federal Republic of Germany. J Cancer Res Clin Oncol 1990; 116: 100-103.
9. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Childrens Cancer Group phase III trial. J Clin Oncol 1993; 11: 527-537.
10. Littman P, Coccia P, Bleyer WA, et al. Central nervous system (CNS) prophylaxis in children with low risk acute lymphoblastic leukemia (ALL). Int J Radiat Oncol Biol Phys 1987; 13: 1443-1449.
11. Sullivan MP, Chen T, Dyment PG, et al. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: A pediatric oncology group study. Blood 1982; 60: 948-958.
12. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A Childrens Cancer Group report. J Clin Oncol 1993; 11: 520-526.
13. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325: 1682-1687.
14. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 2003; 101: 3809-3817.
15. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211-1218.
16. Dinndorf PA, Gootenberg J, Cohen MH, et al. FDA drug approval summary: Pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 2007; 12: 991-998.
17. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group Study. J Clin Oncol 2009; 27: 5175-5181.
18. Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: A report from the Children's Oncology Group. J Clin Oncol 2005; 23: 3376-3382.
19. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730-2741.
20. Matloub Y, Bostrom BC, Hunger SP, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 2011; 118: 243-251.
21. Choi SI, Simone JV. Acute nonlymphocytic leukemia in 171 children. Med Pediatr Oncol 1976; 2: 119-146.
22. Baehner RL, Bernstein ID, Sather H, et al. Improved remission induction rate with D-ZAPO but unimproved remission duration with addition of immunotherapy to chemotherapy in previously untreated children with ANLL. Med Pediatr Oncol 1979; 7: 127-139.
23. Chard RL Jr, Finklestein JZ, Sonley MJ, et al. Increased survival in childhood acute nonlymphocytic leukemia after treatment with prednisone, cytosine arabinoside, 6-thioguanine, cyclophosphamide, and oncovin (PATCO) combination chemotherapy. Med Pediatr Oncol 1978; 4: 263-273.
24. Nesbit ME Jr, Buckley JD, Feig SA, et al. Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: A report from the Childrens Cancer Group. J Clin Oncol 1994; 12: 127-135.
25. Thomas ED, Buckner CD, Clift RA, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 1979; 301: 597-599.
26. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: A report from the children's oncology group. Blood 2008; 111: 1044-1053.
27. Wells RJ, Woods WG, Buckley JD, et al. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: A Childrens Cancer Group study. J Clin Oncol 1994; 12: 2367-2377.
28. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97: 56-62.
29. Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 1990; 75: 27-32.
30. Capizzi RL, Poole M, Cooper MR, et al. Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase. Blood 1984; 63: 694-700.
31. Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia. Cancer 1990; 66: 1106-1113.
32. Dusenbery KE, Howells WB, Arthur DC, et al. Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: A report from the Children's Cancer Group. J Pediatr Hematol Oncol 2003; 25: 760-768.
33. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. Blood 1996; 87: 4979-4989.
34. Creutzig U, Ritter J, Zimmermann M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: Results of study AML-BFM 93. AML-BFM Study Group. Leukemia 2001; 15: 348-354.
35. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997; 89: 2311-2318.
36. Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: Results of AML-BFM 98. J Clin Oncol 2006; 24: 4499-4506.
37. Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19: 2130-2138.
38. Mulrooney DA, Dover DC, Li S, et al. Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: A report from the Childhood Cancer Survivor Study. Cancer 2008; 112: 2071-2079.
39. Reulen RC, Winter DL, Frobisher C, et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA 2010; 304: 172-179.
40. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 2010; 28: 1308-1315.
41. Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet 2009; 373: 1550-1561.
42. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999; 107: 69-79.
43. Horan JT, Alonzo TA, Lyman GH, et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: The Children's Oncology Group. J Clin Oncol 2008; 26: 5797-5801.
44. Balduzzi A, Gooley T, Anasetti C, et al. Unrelated donor marrow transplantation in children. Blood 1995; 86: 3247-3256.
45. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996; 335: 157-166.
46. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997; 89: 3864-3872.
47. Gregory J, Kim H, Alonzo T, et al. Treatment of children with acute promyelocytic leukemia: Results of the first North American Intergroup trial INT0129. Pediatr Blood Cancer 2009; 53: 1005-1010.
48. Testi AM, Biondi A, Lo Coco F, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005; 106: 447-453.
49. Meshinchi S, Stirewalt DL, Alonzo TA, et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood 2003; 102: 1474-1479.
50. Sievers EL, Lange BJ, Buckley JD, et al. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. J Natl Cancer Inst 1996; 88: 1483-1488.
51. Kaplan HS. On the natural history, treatment, and prognosis of Hodgkin's disease. Harvey lectures, 1968-1969. New York: Academic Press; 1970. pp. 215-259.
52. Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970; 73: 881-895.
53. Donaldson SS, Kaplan HS. Complications of treatment of Hodgkin's disease in children. Cancer Treat Rep 1982; 66: 977-989.
54. Donaldson SS, Link MP. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J Clin Oncol 1987; 5: 742-749.
55. Bonadonna G, Santoro A. ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 1982; 9: 21-35.
56. Hudson MM, Greenwald C, Thompson E, et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol 1993; 11: 100-108.
57. Hunger SP, Link MP, Donaldson SS. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: The Stanford experience. J Clin Oncol 1994; 12: 2160-2166.
58. Schellong G, Hornig I, Schwarze EW, et al. Risk factor adapted treatment of Hodgkin's lymphoma in childhood: Strategies and results of three consecutive multicenter studies in the Federal Republic of Germany. Recent Results Cancer Res 1989; 117: 205-213.
59. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-1484.
60. Hutchinson RJ, Fryer CJ, Davis PC, et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: Results of the Children's Cancer Group Phase III Trial. J Clin Oncol 1998; 16: 897-906.
61. van Dalen EC, van der Pal HJ, Kok WE, et al. Clinical heart failure in a cohort of children treated with anthracyclines: A long-term follow-up study. Eur J Cancer 2006; 42: 3191-3198.
62. Dorffel W, Luders H, Ruhl U, et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: Analysis and outlook. Klin Padiatr 2003; 215: 139-145.
63. Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: The results of P9425. Blood 2009; 114: 2051-2059.
64. Tebbi CK, Mendenhall N, London WB, et al. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: A Pediatric Oncology Group (POG) study. Pediatr Blood Cancer 2006; 46: 198-202.
65. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630-637.
66. Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007; 109: 2736-2743.
67. Murphy SB, Fairclough DL, Hutchison RE, et al. Non-Hodgkin's lymphomas of childhood: An analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 1989; 7: 186-193.
68. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients. Blood 2007; 109: 2773-2780.
69. Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM group report. Blood 2000; 95: 416-421.
70. Aur RJ, Hustu HO, Simone JV, et al. Therapy of localized and regional lymphosarcoma of childhood. Cancer 1971; 27: 1328-1331.
71. Meadows AT, Jenkin RD, Anderson J, et al. A new therapy schedule for pediatric non-Hodgkin lymphoma toxicity with preliminary results. Med Pediatr Oncol 1980; 8: 15-24.
72. Murphy SB, Hustu HO. A randomized trial of combined modality therapy of childhood non-Hodgkin's lymphoma. Cancer 1980; 45: 630-637.
73. Weinstein HJ, Lack EE, Cassady JR. APO therapy for malignant lymphoma of large cell "histiocytic" type of childhood: Analysis of treatment results for 29 patients. Blood 1984; 64: 422-426.
74. Wollner N, Burchenal JH, Lieberman PH, et al. Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy. Cancer 1976; 37: 123-134.
75. Anderson JR, Jenkin RD, Wilson JF, et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: A report of CCG-551 from the Childrens Cancer Group. J Clin Oncol 1993; 11: 1024-1032.
76. Murphy SB, Bowman WP, Abromowitch M, et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 1986; 4: 1732-1739.
77. Patte C, Philip T, Rodary C, et al. Improved survival rate in children with stage III and IV B cell non-Hodgkin's lymphoma and leukemia using multi-agent chemotherapy: Results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol 1986; 4: 1219-1226.
78. Philip T, Pinkerton R, Biron P, et al. Effective multiagent chemotherapy in children with advanced B-cell lymphoma: Who remains the high risk patient? Br J Haematol 1987; 65: 159-164.
79. Reiter A, Schrappe M, Ludwig WD, et al. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: A report of three consecutive studies of the BFM group. Blood 1992; 80: 2471-2478.
80. Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin's lymphomas of childhood and adolescence: Results of a treatment stratified for biologic subtypes and stage-A report of the Berlin-Frankfurt-Munster Group. J Clin Oncol 1995; 13: 359-372.
81. Sullivan MP, Ramirez I. Curability of Burkitt's lymphoma with high-dose cyclophosphamide-high-dose methotrexate therapy and intrathecal chemoprophylaxis. J Clin Oncol 1985; 3: 627-636.
82. Patte C, Philip T, Rodary C, et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: Results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 1991; 9: 123-132.
83. Schwenn MR, Blattner SR, Lynch E, et al. HiC-COM: A 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol 1991; 9: 133-138.
84. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study. Leukemia 1999; 13: 335-342.
85. Goldberg JM, Silverman LB, Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 2003; 21: 3616-3622.
86. Hvizdala EV, Berard C, Callihan T, et al. Nonlymphoblastic lymphoma in children-Histology and stage-related response to therapy: A Pediatric Oncology Group study. J Clin Oncol 1991; 9: 1189-1195.
87. Link MP, Donaldson SS, Berard CW, et al. Results of treatment of childhood localized non-Hodgkin's lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med 1990; 322: 1169-1174.
88. Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: A pediatric oncology group study. J Clin Oncol 1996; 14: 1252-1261.
89. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14: 925-934.
90. Patte C, Auperin A, Michon J, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001; 97: 3370-3379.
91. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999; 94: 3294-3306.
92. Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: A report of the BFM Group Study NHL-BFM95. Blood 2005; 105: 948-958.
93. Burkhardt B, Woessmann W, Zimmermann M, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 2006; 24: 491-499.
94. Sandlund JT, Pui CH, Zhou Y, et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: Results of St Jude NHL13 study. Leukemia 2009; 23: 1127-1130.
95. Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: Results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: A Pediatric Oncology Group phase III trial. J Clin Oncol 2005; 23: 541-547.
96. Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: A prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 1994; 12: 899-908.
97. Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol 2010; 28: 3115-3121.
98. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-1821.
99. Kawedia JD, Kaste SC, Pei D, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 2011; 117: 2340-2347, quiz 2556.
100. Temming P, Qureshi A, Hardt J, et al. Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: Retrospective cohort study in a single centre in the United Kingdom. Pediatr Blood Cancer 2011; 56: 625-630.